10/507490

DT04 Rec'd PCT/PTO 13 SEP 2004

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-14 (Cancelled)

15. (New) A compound of the following formula (I):



or a pharmaceutically acceptable salt thereof,

wherein:

n is 1;

X is hydrogen, O-R, NH-R, NO_2, or N-(C=O)-R;

X' is hydrogen or CH_2OH;

Y is $O-R_1$, $NH-R_1$;

R is hydrogen, linear or branched alkyl, linear or branched acyl, substituted or non-substituted aryl or aralkyl residue;

R_1 is hydrogen, linear or branched alkyl, linear or branched acyl, substituted or non-substiuted aryl, alkylcarboxy ester or alkyl-N-R_2R_3;

R_2 and R_3 are independently hydrogen or an alkyl group;

alkyl is an alkyl group having from 1 to 24 carbon atoms, preferably from 3 carbon atoms to 20 carbon atoms, most preferably from 5 carbon atoms to 15 carbon atoms;

wherein acyl is an aliphatic saturated or unsaturated C_1 - C_{24} acyl group, preferably an acyl group having an even number of carbon atoms, and most preferably an acyl group derived from a natural fatty acid such as a saturated aliphatic acyl group or an unsaturated aliphatic acyl group; and

aryl is a to a mono- or poly-carbocyclic aryl group, most preferably phenyl, optionally substituted by C_1-C_4 -alkyl, halogen and/or hydroxy;

provided that X and X' cannot both be hydrogen; that when X is NH-R, where R is a linear or branched acyl, then Y is not OR_1 where R_1 is a 4-nitrophenyl; and that when X' is CH_2OH, then X is NH-R or NO_2.

16. (New) A compound according to claim 15, wherein the acyl moiety is selected from the group comprising of acetyl, butyryl, caproyl, octanoyl, decanoyl, lauroyl, myristyl,

palmitoyl and stearoyl, palmitoleyl, oleyl, linoleyl, and ricinoleyl.

17. (New) A compound according to claim 15 wherein Y is OH and X is O-R or NH-R; wherein R is a linear or branched alkyl or linear or branched acyl.

18. (New) A compound according to claim 15 wherein X is hydrogen and Y is O-R_1 or NH-R_1; wherein R_1 is a linear or branched acyl.

19. (New) Compounds of formula I according to claim 15 selected from the group consisting of:

(a) 1,3-cyclic propandiol phosphate-5-oleoyl;

(b) 1,3-cyclic propandiol phosphate-5- benzyloxy;

(c) 1,3-cyclic propandiol phosphate-5- benzylamino;

(d) 1,3-cyclic propandiol phosphate-5- caproylamido;

(e) 1,3-cyclic propandiol phosphate-2-benzyloxy;

(f) 1,3-cyclic propandiol phosphate-2- acetyloxy;

(g) 1,3-cyclic propandiol phosphate-2-methylamino;

(h) 1,3-cyclic propandiol phosphate-5-glycine ethylester;

(i) 2-dimethylamine ethyl ester 1,3-cyclic propanediol phosphate;

(j) 1,3-cyclic propanediol phosphoamidate;

(k) 1,3-cyclic propanediol N-ethyl phosphoamidate;

(l) 1,3-cyclic propanediol phosphoamidate glycine ethylester;

(m) 2-benzyloxy 1,3-chloropropanediol phosphate;

(n) 2-caproimido 1,3-chloropropanediol phosphate;

(o) 5-amino-5-hydroxymethyl-2-oxo-2λ5-[1,3,2]dioxaphosphinan-2-ol; and

(p) 5-nitro-5-hydroxymethyl-2-oxo-2λ5-[1,3,2]dioxaphosphinan-2-ol;

or a pharmaceutically acceptable salt thereof.

20. (New) A pharmaceutical composition comprising a pharmaceutical acceptable carrier and, as an active ingredient, a compound (I) in accordance with claim 15.

21. (New) A pharmaceutical composition according to claim 20, for promoting neural activity.

22. (New) A pharmaceutical composition according to claim 21, wherein said neural activity is selected from the group consisting of promotion of neuronal outgrowth, promotion of nerve growth, provision of dopaminotrophic supporting environment in a diseased portion of the brain, prevention of nerve degeneration and nerve rescue.

23. (New) A pharmaceutical composition according to claim 22, wherein said neuronal outgrowth is axonal growth or axonal branching.

24. (New) A pharmaceutical composition according to claim 20, for the prevention or treatment of disorders and diseases which can be prevented or treated by activating neural cells.

25. (New) A pharmaceutical composition according to claim 22, wherein said disorder and disease are schizophrenia, dementia or disorder resulting from learning disabilities.

26. (New) A pharmaceutical composition according to claim 20 wherein the compound of formula I is selected from the group consisting of

(a) 1,3-cyclic propandiol phosphate-5-oleoyl;

(b) 1,3-cyclic propandiol phosphate-5- benzyloxy;

(c) 1,3-cyclic propandiol phosphate-5- benzylamino;

(d) 1,3-cyclic propandiol phosphate-5- caproylamido;

(e) 1,3-cyclic propandiol phosphate-2-benzyloxy;

(f) 1,3-cyclic propandiol phosphate-2- acetyloxy;

(g) 1,3-cyclic propandiol phosphate-2-methylamino;

(h) 1,3-cyclic propandiol phosphate-5-glycine ethylester;

(i) 2-dimethylamine ethyl ester 1,3-cyclic propanediol phosphate;

(j) 1,3-cyclic propanediol phosphoamidate;

(k) 1,3-cyclic propanediol N-ethyl phosphoamidate;

(l) 1,3-cyclic propanediol phosphoamidate glycine ethylester;

(m) 2-benzyloxy 1,3-chloropropanediol phosphate;

(n) 2-caproimido 1,3-chloropropanediol phosphate;

(o) 5-amino-5-hydroxymethyl-2-oxo-2λ5-[1,3,2]dioxaphosphinan-2-ol; and

(p) 5-nitro-5-hydroxymethyl-2-oxo-2λ5-[1,3,2]dioxaphosphinan-2-ol;

or a pharmaceutically acceptable salt thereof.

27. (New) A method of treating disorders and diseases which can be prevented or treated by activating neural cells comprising administering to the individual in need a therapeutically effective amount of a compound in accordance with claim 15.

28. (New) A method according to claim 27, wherein said neural activity is selected from the group consisting of promotion of neuronal outgrowth, promotion of nerve growth, provision of dopaminotrophic supporting environment in a diseased portion of the brain, prevention of nerve degeneration and nerve rescue.